Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine
Copyright © 2012 Elsevier España, S.L. and AEEH y AEG. All rights reserved..
INTRODUCTION: In ulcerative colitis, aminosalicylates are the mainstay of maintenance therapy. Sulfasalazine was the first aminosalicylic used in the maintenance therapy of this disease. Later, mesalazine was preferred due to its supposedly better tolerability. However, recent studies indicate certain benefits of the use of sulfasalazine because of its possible superior effectiveness. The aim of this study was to determine whether patients with ulcerative colitis poorly controlled by mesalazine as maintenance therapy respond to sulfasalazine, thus avoiding the use of immunosuppressive or biological therapies.
METHODS: The Inflammatory Bowel Disease Clinic of the Ramón y Cajal Hospital maintains a database in which all drug exposures are registered. We selected patients poorly controlled with mesalazine who had received sulfasalazine as rescue maintenance therapy. We determined the percentage of patients poorly controlled with mesalazine who responded to sulfasalazine.
RESULTS: Of 415 patients with ulcerative colitis, 49 had been treated with sulfasalazine at some time. Of these, sulfasalazine was selected as an alternative therapy due to poor disease control with mesalazine. The median duration of mesalazine therapy until the switch was 20.8 months, with a median dose of 3.35 g/day. In 21 of the 31 patients (67.7%), sulfasalazine was able to control symptoms and maintain remission.
CONCLUSION: Despite the limitations of this study, we found that 67.7% of patients with ulcerative colitis poorly controlled with mesalazine responded to a switch to sulfasalazine. These patients would normally have progressed to immunosuppressive, biological or surgical treatments. This option merits further studies. Meanwhile sulfasalazine should not be forgotten in the management of ulcerative colitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - 36(2013), 1 vom: 13. Jan., Seite 7-10 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Rescate con sulfasalazina antes de inmunosupresores o agentes biológicos en la colitis ulcerosa mal controlada con mesalazina |
|---|
| Beteiligte Personen: |
Martínez González, Javier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3XC8GUZ6CB |
|---|
| Anmerkungen: |
Date Completed 03.02.2014 Date Revised 28.01.2013 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gastrohep.2012.08.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM223023620 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM223023620 | ||
| 003 | DE-627 | ||
| 005 | 20231224055723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2012.08.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0743.xml |
| 035 | |a (DE-627)NLM223023620 | ||
| 035 | |a (NLM)23195755 | ||
| 035 | |a (PII)S0210-5705(12)00267-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Martínez González, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine |
| 246 | 3 | 3 | |a Rescate con sulfasalazina antes de inmunosupresores o agentes biológicos en la colitis ulcerosa mal controlada con mesalazina |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2014 | ||
| 500 | |a Date Revised 28.01.2013 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2012 Elsevier España, S.L. and AEEH y AEG. All rights reserved. | ||
| 520 | |a INTRODUCTION: In ulcerative colitis, aminosalicylates are the mainstay of maintenance therapy. Sulfasalazine was the first aminosalicylic used in the maintenance therapy of this disease. Later, mesalazine was preferred due to its supposedly better tolerability. However, recent studies indicate certain benefits of the use of sulfasalazine because of its possible superior effectiveness. The aim of this study was to determine whether patients with ulcerative colitis poorly controlled by mesalazine as maintenance therapy respond to sulfasalazine, thus avoiding the use of immunosuppressive or biological therapies | ||
| 520 | |a METHODS: The Inflammatory Bowel Disease Clinic of the Ramón y Cajal Hospital maintains a database in which all drug exposures are registered. We selected patients poorly controlled with mesalazine who had received sulfasalazine as rescue maintenance therapy. We determined the percentage of patients poorly controlled with mesalazine who responded to sulfasalazine | ||
| 520 | |a RESULTS: Of 415 patients with ulcerative colitis, 49 had been treated with sulfasalazine at some time. Of these, sulfasalazine was selected as an alternative therapy due to poor disease control with mesalazine. The median duration of mesalazine therapy until the switch was 20.8 months, with a median dose of 3.35 g/day. In 21 of the 31 patients (67.7%), sulfasalazine was able to control symptoms and maintain remission | ||
| 520 | |a CONCLUSION: Despite the limitations of this study, we found that 67.7% of patients with ulcerative colitis poorly controlled with mesalazine responded to a switch to sulfasalazine. These patients would normally have progressed to immunosuppressive, biological or surgical treatments. This option merits further studies. Meanwhile sulfasalazine should not be forgotten in the management of ulcerative colitis | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Sulfasalazine |2 NLM | |
| 650 | 7 | |a 3XC8GUZ6CB |2 NLM | |
| 650 | 7 | |a Mesalamine |2 NLM | |
| 650 | 7 | |a 4Q81I59GXC |2 NLM | |
| 700 | 1 | |a Busto Bea, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Mesonero Gismero, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Parejo Carbonell, Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a Garrido, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a López San Román, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g 36(2013), 1 vom: 13. Jan., Seite 7-10 |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2013 |g number:1 |g day:13 |g month:01 |g pages:7-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2012.08.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2013 |e 1 |b 13 |c 01 |h 7-10 | ||